RSS
synthetic promotor
Collaboration announced to develop gene therapy for Parkinson’s
Gene control company, Synpromics, has revealed its collaboration with University College London (UCL) for the generation of a range of synthetic gene promotors for the central nervous system (CNS) to develop a therapy for Parkinson’s disease. Read more
Synpromics completes financing round of £5.2M
Synthetic promotor and gene control company, Synpromics, has raised £5.2 million of new investment. The funds were raised from existing investors. Read more
